Corestemchemon
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Corestemchemon develops and supplies stem-cell therapies, medicines that use living cells to treat rare and hard-to-cure diseases, to patients in South Korea, and also runs a contract research division that conducts pre-clinical (animal-based) safety and efficacy testing on behalf of drug developers.
It is listed on KOSDAQ, South Korea's tech and small-cap exchange. The business operates two distinct divisions: a biopharmaceuticals arm that manufactures and supplies approved stem-cell treatments, and a non-clinical contract research arm that provides testing services to outside clients.
Summary is AI-generated and may contain errors · figures from DART filings
The company absorbed its subsidiary Chemon, one of South Korea's leading non-clinical contract research organisations, through a merger, creating its current two-division structure.
Corestemchemon in five facts
What does Corestemchemon do?
Corestemchemon develops and supplies stem-cell therapies, medicines that use living cells to treat rare and hard-to-cure diseases, to patients in South Korea, and also runs a contract research division that conducts pre-clinical (animal-based) safety and efficacy testing on behalf of drug developers.
Where is Corestemchemon listed and in which sector?
Corestemchemon (Korean name: 코아스템켐온) trades under KRX code 166480 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Corestemchemon?
Its market capitalisation was US$69.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Corestemchemon's latest annual revenue and operating profit?
For fiscal year 2025, Corestemchemon reported revenue of US$15.2M, an operating loss of US$16M and a net loss of US$20.3M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 29.9% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.